George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
News|Articles|August 2, 2024
Nephrology Month in Review: July 2024
Author(s)Abigail Brooks, MA
This July 2024 month in review highlights renal pipeline updates, new patient-focused CKD guidelines, and other top nephrology news and research.
Advertisement
Advertisement
July was a promising start to the second half of what has been a strong year in nephrology thus far. Characterized by US Food and Drug Administration news and other renal pipeline updates, new guidelines from the American Kidney Fund, and prognostic research in
Related to this article
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Advertisement
Advertisement